Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection : A prospective cohort study
Copyright © 2022 Bruni, Charitos, Lampart, Moser, Siegemund, Bingisser, Osswald, Bassetti, Twerenbold, Trendelenburg, Rentsch and Osthoff..
Background: Thromboinflammation may influence disease outcome in COVID-19. We aimed to evaluate complement and endothelial cell activation in patients with confirmed COVID-19 compared to controls with clinically suspected but excluded SARS-CoV-2 infection.
Methods: In a prospective, observational, single-center study, patients presenting with clinically suspected COVID-19 were recruited in the emergency department. Blood samples on presentation were obtained for analysis of C5a, sC5b-9, E-selectin, Galectin-3, ICAM-1 and VCAM-1.
Results: 153 cases and 166 controls (suffering mainly from non-SARS-CoV-2 respiratory viral infections, non-infectious inflammatory conditions and bacterial pneumonia) were included. Hospital admission occurred in 62% and 45% of cases and controls, respectively. C5a and VCAM-1 concentrations were significantly elevated and E-selectin concentrations decreased in COVID-19 out- and inpatients compared to the respective controls. However, relative differences in outpatients vs. inpatients in most biomarkers were comparable between cases and controls. Elevated concentrations of C5a, Galectin-3, ICAM-1 and VCAM-1 on presentation were associated with the composite outcome of ICU- admission or 30-day mortality in COVID-19 and controls, yet more pronounced in COVID-19. C5a and sC5b-9 concentrations were significantly higher in COVID-19 males vs. females, which was not observed in the control group.
Conclusions: Our data indicate an activation of the complement cascade and endothelium in COVID-19 beyond a nonspecific inflammatory trigger as observed in controls (i.e., "over"-activation).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 13(2022) vom: 25., Seite 941742 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bruni, Flavio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.10.2022 Date Revised 12.10.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2022.941742 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347189512 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347189512 | ||
| 003 | DE-627 | ||
| 005 | 20231226205354.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.941742 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347189512 | ||
| 035 | |a (NLM)36203596 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bruni, Flavio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection |b A prospective cohort study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.10.2022 | ||
| 500 | |a Date Revised 12.10.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Bruni, Charitos, Lampart, Moser, Siegemund, Bingisser, Osswald, Bassetti, Twerenbold, Trendelenburg, Rentsch and Osthoff. | ||
| 520 | |a Background: Thromboinflammation may influence disease outcome in COVID-19. We aimed to evaluate complement and endothelial cell activation in patients with confirmed COVID-19 compared to controls with clinically suspected but excluded SARS-CoV-2 infection | ||
| 520 | |a Methods: In a prospective, observational, single-center study, patients presenting with clinically suspected COVID-19 were recruited in the emergency department. Blood samples on presentation were obtained for analysis of C5a, sC5b-9, E-selectin, Galectin-3, ICAM-1 and VCAM-1 | ||
| 520 | |a Results: 153 cases and 166 controls (suffering mainly from non-SARS-CoV-2 respiratory viral infections, non-infectious inflammatory conditions and bacterial pneumonia) were included. Hospital admission occurred in 62% and 45% of cases and controls, respectively. C5a and VCAM-1 concentrations were significantly elevated and E-selectin concentrations decreased in COVID-19 out- and inpatients compared to the respective controls. However, relative differences in outpatients vs. inpatients in most biomarkers were comparable between cases and controls. Elevated concentrations of C5a, Galectin-3, ICAM-1 and VCAM-1 on presentation were associated with the composite outcome of ICU- admission or 30-day mortality in COVID-19 and controls, yet more pronounced in COVID-19. C5a and sC5b-9 concentrations were significantly higher in COVID-19 males vs. females, which was not observed in the control group | ||
| 520 | |a Conclusions: Our data indicate an activation of the complement cascade and endothelium in COVID-19 beyond a nonspecific inflammatory trigger as observed in controls (i.e., "over"-activation) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a E-Selectin | |
| 650 | 4 | |a ICAM-1 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a VCAM-1 | |
| 650 | 4 | |a complement system | |
| 650 | 4 | |a endothelial cells | |
| 650 | 4 | |a galectin-3 | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a E-Selectin |2 NLM | |
| 650 | 7 | |a Galectin 3 |2 NLM | |
| 650 | 7 | |a Vascular Cell Adhesion Molecule-1 |2 NLM | |
| 650 | 7 | |a Intercellular Adhesion Molecule-1 |2 NLM | |
| 650 | 7 | |a 126547-89-5 |2 NLM | |
| 650 | 7 | |a Complement System Proteins |2 NLM | |
| 650 | 7 | |a 9007-36-7 |2 NLM | |
| 700 | 1 | |a Charitos, Panteleimon |e verfasserin |4 aut | |
| 700 | 1 | |a Lampart, Maurin |e verfasserin |4 aut | |
| 700 | 1 | |a Moser, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Siegemund, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Bingisser, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a Osswald, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Bassetti, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Twerenbold, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Trendelenburg, Marten |e verfasserin |4 aut | |
| 700 | 1 | |a Rentsch, Katharina M |e verfasserin |4 aut | |
| 700 | 1 | |a Osthoff, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022) vom: 25., Seite 941742 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:25 |g pages:941742 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.941742 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 25 |h 941742 | ||